In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

The desmoplastic stroma in solid tumors presents a formidable challenge to
immunotherapies that rely on endogenous or adoptively transferred T cells, however, the …

Cancer immunotherapy effect can be greatly enhanced by other methods to induce
immunogenic cell death (ICD), which has profoundly affected immunotherapy as a highly …

The demise of cells in various ways enables the body to clear unwanted cells. Studies over
the years revealed distinctive molecular mechanisms and functional consequences of …

Promoting innate immunity through pyroptosis induction or the cyclic GMP‐AMP synthase‐
stimulator of interferon gene (cGAS‐STING) pathway activation has emerged as a potent …

T cells are the major arm of the immune system responsible for controlling and regressing
cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR …

Cancer stemness, defined as the self-renewal and tumor-initiation potential of cancer stem
cells (CSCs), is a cancer biology property featuring activation of CSC signaling networks …

In this prospective, interventional phase 1 study for individuals with advanced sarcoma, we
infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) …